Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Texas Instruments reported lower profit and revenue in the fourth quarter, while its first-quarter outlook missed expectations. The chipmaker reported a profit of $1.21 billion on revenue of $4.01 ...

Shares fall 4.3%, to $191.93, in postmarket trading. Allurion Technologies said it would initiate a clinical study on the combination of certain weight-loss drugs and its Allurion program with the ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

09:42 EST Allurion Technologies (ALUR) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best ...

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today ...